The development of new, clinically-effective Antibody Drug Conjugates (ADCs) has been hampered by a lack of suitable target antigens, particularly those which target both cancer and cancer-supporting stromal cells. Oncofetal chondroitin sulfate (ofCS) is an attractive target in this regard, as it is not only broadly expressed across many solid tumors while being largely absent […]
